- Home
- IMCR vs STEW Comparison
IMCR vs STEW Comparison
Compare IMCR & STEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- STEW
- Stock Information
- Founded
- IMCR 2008
- STEW 1972
- Country
- IMCR United Kingdom
- STEW United States
- Employees
- IMCR N/A
- STEW N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- STEW Investment Managers
- Sector
- IMCR Health Care
- STEW Finance
- Exchange
- IMCR Nasdaq
- STEW Nasdaq
- Market Cap
- IMCR 1.8B
- STEW 1.7B
- IPO Year
- IMCR 2021
- STEW N/A
- Fundamental
- Price
- IMCR $37.20
- STEW $18.47
- Analyst Decision
- IMCR Buy
- STEW
- Analyst Count
- IMCR 9
- STEW 0
- Target Price
- IMCR $57.00
- STEW N/A
- AVG Volume (30 Days)
- IMCR 284.7K
- STEW 84.5K
- Earning Date
- IMCR 11-05-2025
- STEW 01-01-0001
- Dividend Yield
- IMCR N/A
- STEW 3.71%
- EPS Growth
- IMCR N/A
- STEW N/A
- EPS
- IMCR N/A
- STEW 1.44
- Revenue
- IMCR $356,145,000.00
- STEW N/A
- Revenue This Year
- IMCR $31.83
- STEW N/A
- Revenue Next Year
- IMCR $8.50
- STEW N/A
- P/E Ratio
- IMCR N/A
- STEW $10.34
- Revenue Growth
- IMCR 26.78
- STEW N/A
- 52 Week Low
- IMCR $23.15
- STEW $11.97
- 52 Week High
- IMCR $39.33
- STEW $14.94
- Technical
- Relative Strength Index (RSI)
- IMCR 76.55
- STEW 67.65
- Support Level
- IMCR $31.85
- STEW $17.93
- Resistance Level
- IMCR $33.08
- STEW $18.58
- Average True Range (ATR)
- IMCR 1.28
- STEW 0.14
- MACD
- IMCR 0.50
- STEW 0.03
- Stochastic Oscillator
- IMCR 100.00
- STEW 74.04
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.